[Skip to Navigation]
Sign In
February 1966

Primary Treatment of Choriocarcinoma With Methotrexate

Author Affiliations

From the US Air Force Hospital, Keesler Air Force Base, Miss.

Arch Surg. 1966;92(2):301-303. doi:10.1001/archsurg.1966.01320200141021

IN RECENT years there has been a surge of interest in choriocarcinoma due mainly to the work of Dr. R. Hertz and M. C. Li and their associates with chemotherapeutic agents, particularly methotrexate. Hertz has reported complete remission of one to five year's duration in 47.5% of 63 patients treated with methotrexate.6 Some of the remainder have shown at least transient response to vinblastine sulfate, an oncolytic alkaloid. Presently work is being carried out with the primary use of dactinomycin.

The bizarre behavior of trophoblastic growths has been emphasized by many authors.1,2,4,5,7,8,9 This makes premature and overzealous interpretation of new therapeutic measures hazardous. In reviewing the cases of the Albert Mathieu Chorioepithelioma Registry, Brewer and associates3 found five-year survival of 21 out of 147 patients with choriocarcinoma who were treated surgically. Of these 21 patients, six had metastatic lesions.

This presentation aims to contribute two cases of

Add or change institution